[go: up one dir, main page]

GB1428361A - Safeguarded medicinal compositions - Google Patents

Safeguarded medicinal compositions

Info

Publication number
GB1428361A
GB1428361A GB702672A GB702672A GB1428361A GB 1428361 A GB1428361 A GB 1428361A GB 702672 A GB702672 A GB 702672A GB 702672 A GB702672 A GB 702672A GB 1428361 A GB1428361 A GB 1428361A
Authority
GB
United Kingdom
Prior art keywords
drug
emetic
safeguarded
feb
enteric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB702672A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to GB702672A priority Critical patent/GB1428361A/en
Publication of GB1428361A publication Critical patent/GB1428361A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1428361 Safeguarded medicaments A GRANT 15 Feb 1973 [15 Feb 1972] 7026/72 Heading A5B Pharmaceutical compositions in the form of capsules and slugs comprise a drug (e.g. aspirin or a barbiturate) and an emetic, the quantity of the latter being sufficient to produce emesis When the drug is administered at overdose levels, the availability of the drug being delayed relative to that of the emetic by a coating thereon of a third substance which delays release of the drug but not the emetic. Specific reference is made to a capsule filling comprising pellets of enteric-coated drug and non- enteric pellets containing emetic of similar appearance. Suitable emetics are emetine and cephaelin drugs, ipecacuanha extract, mustard, ZnSO4 and apomorphine.
GB702672A 1972-02-15 1972-02-15 Safeguarded medicinal compositions Expired GB1428361A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB702672A GB1428361A (en) 1972-02-15 1972-02-15 Safeguarded medicinal compositions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB702672A GB1428361A (en) 1972-02-15 1972-02-15 Safeguarded medicinal compositions

Publications (1)

Publication Number Publication Date
GB1428361A true GB1428361A (en) 1976-03-17

Family

ID=9825235

Family Applications (1)

Application Number Title Priority Date Filing Date
GB702672A Expired GB1428361A (en) 1972-02-15 1972-02-15 Safeguarded medicinal compositions

Country Status (1)

Country Link
GB (1) GB1428361A (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4269820A (en) 1977-02-11 1981-05-26 Imperial Chemical Industries Limited Safeguarded toxic chemical compositions containing effective emesis-inducing S-triazolo-[1,5-α]pyrimidine derivatives
GB2162061A (en) * 1984-05-03 1986-01-29 Bibhuti B Bardhan Controlled time release therapeutic composition having means for counteracting overdosage
WO2004054562A1 (en) * 2002-12-16 2004-07-01 Pharmaquest Ltd. Method for preventing abuse of methylphenidate
EP1581188A4 (en) * 2003-01-10 2006-04-05 Mutual Pharmaceutical Co Pharmaceutical safety dosage forms
WO2010081920A1 (en) * 2009-01-15 2010-07-22 Raquel Miriam Rodriguez Valle Incorporation of an emetic in drugs as a safety system in respect of possible overdoses, particularly in drugs acting on the central nervous system such as benzodiazepine and derivatives, barbiturates... and drugs for paediatric use
EP1893183A4 (en) * 2005-06-13 2010-08-18 Paul Rosenberg Emetic embedded capsule
US7981439B2 (en) * 2003-11-26 2011-07-19 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of drugs susceptible to abuse and dosage forms thereof
US8901113B2 (en) 2009-09-30 2014-12-02 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
US8940330B2 (en) 2011-09-19 2015-01-27 Orexo Ab Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
US9060950B2 (en) 2005-06-13 2015-06-23 Paul H. Rosenberg, Proximate Concepts, LLC. Emetic embedded capsule
US9101636B2 (en) 2012-11-30 2015-08-11 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
US11103581B2 (en) 2015-08-31 2021-08-31 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4269820A (en) 1977-02-11 1981-05-26 Imperial Chemical Industries Limited Safeguarded toxic chemical compositions containing effective emesis-inducing S-triazolo-[1,5-α]pyrimidine derivatives
GB2162061A (en) * 1984-05-03 1986-01-29 Bibhuti B Bardhan Controlled time release therapeutic composition having means for counteracting overdosage
WO2004054562A1 (en) * 2002-12-16 2004-07-01 Pharmaquest Ltd. Method for preventing abuse of methylphenidate
EP1581188A4 (en) * 2003-01-10 2006-04-05 Mutual Pharmaceutical Co Pharmaceutical safety dosage forms
US7524515B2 (en) 2003-01-10 2009-04-28 Mutual Pharmaceuticals, Inc. Pharmaceutical safety dosage forms
US7919120B2 (en) 2003-01-10 2011-04-05 Mutual Pharmaceuticals, Inc. Pharmaceutical safety dosage forms
US9492443B2 (en) 2003-11-26 2016-11-15 Acura Pharmaceuticals, Inc. Abuse deterrent compositions and methods of making same
US7981439B2 (en) * 2003-11-26 2011-07-19 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of drugs susceptible to abuse and dosage forms thereof
US8637540B2 (en) 2003-11-26 2014-01-28 Acura Pharmaceuticals Compositions for deterring abuse of opioid containing dosage forms
US8822489B2 (en) 2003-11-26 2014-09-02 Acura Pharmaceuticals Abuse deterrent compositions and methods of making same
US9060950B2 (en) 2005-06-13 2015-06-23 Paul H. Rosenberg, Proximate Concepts, LLC. Emetic embedded capsule
EP1893183A4 (en) * 2005-06-13 2010-08-18 Paul Rosenberg Emetic embedded capsule
WO2010081920A1 (en) * 2009-01-15 2010-07-22 Raquel Miriam Rodriguez Valle Incorporation of an emetic in drugs as a safety system in respect of possible overdoses, particularly in drugs acting on the central nervous system such as benzodiazepine and derivatives, barbiturates... and drugs for paediatric use
US8901113B2 (en) 2009-09-30 2014-12-02 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
US10155044B2 (en) 2009-09-30 2018-12-18 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
US8940330B2 (en) 2011-09-19 2015-01-27 Orexo Ab Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
US9259421B2 (en) 2011-09-19 2016-02-16 Orexo Ab Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
US11433066B2 (en) 2011-09-19 2022-09-06 Orexo Ab Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
US9439900B2 (en) 2011-09-19 2016-09-13 Orexo Ab Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
US10946010B2 (en) 2011-09-19 2021-03-16 Orexo Ab Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
US11020387B2 (en) 2011-09-19 2021-06-01 Orexo Ab Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
US11020388B2 (en) 2011-09-19 2021-06-01 Orexo Ab Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
US10874661B2 (en) 2011-09-19 2020-12-29 Orexo Ab Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
US9101636B2 (en) 2012-11-30 2015-08-11 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
US10688184B2 (en) 2012-11-30 2020-06-23 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
US10441657B2 (en) 2012-11-30 2019-10-15 Abuse Deterrent Pharmaceuticals, Llc Methods and compositions for self-regulated release of active pharmaceutical ingredient
US9320796B2 (en) 2012-11-30 2016-04-26 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
US11857629B2 (en) 2012-11-30 2024-01-02 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
US11103581B2 (en) 2015-08-31 2021-08-31 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient

Similar Documents

Publication Publication Date Title
GB1204580A (en) Pharmaceutical dosage forms
GB1428361A (en) Safeguarded medicinal compositions
NO146456C (en) PROCEDURE FOR THE PREPARATION OF Capsule Drugs, Especially For Medication Dosage Capsule
ES428171A1 (en) Tablets containing in their mass controlled-release micro-capsules and process for manufacture of said tablets
CA2145513A1 (en) Pharmaceutical Tablet Capable of Liberating One or More Drugs at Different Release Rates
GB1509979A (en) Pharmaceutical compositions containing aspirin or indomethacin
GB1235787A (en) Sustained release pharmaceutical tablets
GB1298084A (en) Capsules and other self-supporting medicinal packaging means
GB1423985A (en) Pharmaceutical compositions containing bischromonyloxy compounds
ES362231A1 (en) Dimethylbiguanide Derivative
GB791644A (en) Barbiturate pharmaceutical preparations
BE787126A (en) SUBSTITUTED PYRIMIDINES, PROCESSES FOR THE PREPARATION OF THESE COMPOUNDS AND MEDICINAL PRODUCTS CONTAINING THE SAID COMPOUNDS
IL39173A0 (en) 2-(5-nitro-2-furyl)-thieno(2,3-d)pyrimidines and salts thereof,their preparation and pharmaceutical compositions containing them
FR2077913A1 (en) Tablets contg gelatine capsules - for administration of liquid medicaments
GB1147245A (en) Method for the production of slow release pharmaceutical compositions
GB1352392A (en) Phenylisopropylamine derivatives
GB1436714A (en) Medicinal process
Bucci Drug-induced depression and tryptophan metabolism.
CA939564A (en) Manufacture of minute capsules, en masse, and capsule product
GB1153014A (en) Improvements in or relating to An Oral Dose for the Treatment of Tuberculosis
GB1378296A (en) Pharmaceutical composition
GB1346405A (en) Pharmaceutical composition useful as an anti-depressant agent and an anti-parkinsonism agent
GB1185335A (en) A method for producing Protease
GB1454872A (en) Anticonvulsant
JPS5352617A (en) Solid drug coating composition

Legal Events

Date Code Title Description
PS Patent sealed
PCNP Patent ceased through non-payment of renewal fee